Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: out_of_the_loop who wrote (543)	5/6/1999 6:38:00 PM
From: Street Walker	Read Replies (3) \| Respond to of 5582

GUMM - some thoughts on the joint venture The latest press release makes some clarifications as to the structure of who owns ZICAM. zicam.com Zicam is owned by Biodelivery, a private company. Biodelivery is 60% owned by GUMM and 40% owned by Gel Tech. Noteworthy items regarding ZICAM will be required by Biodelivery to make public in a timely matter, since it involves a publically trading company. When news is released on ZICAM, it will now come from Biodelivery and in the body of the message it will have to include GUMM's ticker symbol as a part owner in the company and GelTech being a private owner. GUMM in the past has not been the greatest at puting out news announcements and keeping investors informed. Lets see what Dr. Davidson, CEO of BioDelivery Technologies, and newly appointed CEO of Gel Tech, can do to keep us better informed about ZICAM. Now GUMM can focus on manufacturing functional Chewing GUMM and ZICAM can have full devoted focus by a separate entity. For investors, the only way to own a piece of ZICAM is to own GUMM. Being focused on specific products is to our benefit. >>"We have received a significant amount of interest from other retailers and feel confident that ZICAM(TM) will be available in most major drug, grocery and mass retail chains in the United States during the coming cold season.<< I read the above to include Wal-Mart, K-Mart, etc. Basically everywhere ZICAM will be available for purchase. Shareholders of GUMM will be expecting a news release when we sign on with these retail powerhouses. >>"We also have received a significant amount of unsolicited interest in the product from companies overseas,'' said Davidson. ''As a result, we intend to begin international distribution sooner than we had originally anticipated."<< THIS IS EXCITING: Moving forward ahead of plans - INTERNATIONAL So investors look forward to Dr. Davidson putting out an announcment of who will be the international distributors of ZICAM. Press Releases regarding current distributors of ZICAM was never released under GUMM management and in my opinion was a missed opportunity. I am really hoping BioDelivery Public Relations will be more on the ball, since they are now fully in charge. Shareholders of GUMM also need from Biodelivery a quarterly report of number of units shipped, plans for advertisement (is Geltech contributing their 40% to expenses?) and when they expect to be profitable, and what Universities are conducting the studies on ZICAM. A private company can not withold information if it involves a publically trading company, ie GUMM. I am really excited to see BioDelivery Technologies very first news release. LONG and STRONG GUMM for the Long Term, based on Zicam market and the potential market in functional chewing gums (rumored nicorette and dental gum contracts). Regards, S.W.